Hongrui Tian1, Weiping Liu2, Yuqin Song2, Lan Mi2, Zhen Liu1, Mengfei Liu1, Chuanhai Guo1, Fangfang Liu1, Ying Liu1, Yaqi Pan1, Jun Zhu2, Zhonghu He1, Yang Ke1. 1. Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Laboratory of Genetics, Peking University Cancer Hospital & Institute, Beijing, China. 2. Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, China.
Abstract
INTRODUCTION: This study aimed to evaluate the performance of the Medical-Insurance-System-based Cancer Surveillance System (MIS-CASS) in estimating cancer incidence by comparing the results with the Beijing Cancer Registry (BCR), which is one of the highest-quality population-based cancer registries in China. METHODS: Using lymphoma as an example, we extracted relevant claims data from the administrative systems of medical insurance in Beijing (2012-2020) and estimated the most current lymphoma incidence in Beijing (2019) using a standard data processing procedure. The absolute number of new cases, crude incidence rate, and age-standardized incidence rate of lymphoma were compared with the latest data reported by the BCR (2017). RESULTS: Both lymphoma incidence rates and age distribution of new cases estimated based on MIS-CASS were similar to the BCR data (crude incidence rate: 9.8/100,000 vs. 10.6/100,000). However, because MIS-CASS included more designated hospitals and covered a larger local stationary population irrespective of household registration (hukou), the absolute number of incident lymphoma cases identified by MIS-CASS was 39.1% higher than that reported by the BCR (2,002 vs. 1,439). CONCLUSIONS: The MIS-CASS approach reflected the actual cancer burden in a more complete and timely manner as compared with the current BCR, providing new insights for improving cancer surveillance strategies in China. Copyright and License information: Editorial Office of CCDCW, Chinese Center for Disease Control and Prevention 2021.
INTRODUCTION: This study aimed to evaluate the performance of the Medical-Insurance-System-based Cancer Surveillance System (MIS-CASS) in estimating cancer incidence by comparing the results with the Beijing Cancer Registry (BCR), which is one of the highest-quality population-based cancer registries in China. METHODS: Using lymphoma as an example, we extracted relevant claims data from the administrative systems of medical insurance in Beijing (2012-2020) and estimated the most current lymphoma incidence in Beijing (2019) using a standard data processing procedure. The absolute number of new cases, crude incidence rate, and age-standardized incidence rate of lymphoma were compared with the latest data reported by the BCR (2017). RESULTS: Both lymphoma incidence rates and age distribution of new cases estimated based on MIS-CASS were similar to the BCR data (crude incidence rate: 9.8/100,000 vs. 10.6/100,000). However, because MIS-CASS included more designated hospitals and covered a larger local stationary population irrespective of household registration (hukou), the absolute number of incident lymphoma cases identified by MIS-CASS was 39.1% higher than that reported by the BCR (2,002 vs. 1,439). CONCLUSIONS: The MIS-CASS approach reflected the actual cancer burden in a more complete and timely manner as compared with the current BCR, providing new insights for improving cancer surveillance strategies in China. Copyright and License information: Editorial Office of CCDCW, Chinese Center for Disease Control and Prevention 2021.
Entities:
Keywords:
cancer incidence; medical claims data; population-based cancer registries